Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Asian Stocks Gain Amid Iran Conflict Uncertainty 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Australia's Inflation Eases in February but Core Pressures Persist 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
9 Tips for Avoiding Tax Season Cyber Scams 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
